Additionally, glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) and the novel dual (glucose-dependent insulinotropic peptide) GIP/GLP-1 RA tirzepatide have been shown to attenuate the risk of ischemic stroke, while several studies are currently underway to unfold the full neuroprotective potential of these novel agents [69]. Here, GLP1R is linked to ischemic stroke.